'Spermbots' Could Help Women Trying to Conceive (includes video)
By Phys.org,
Phys.org
| 01. 13. 2016
Sperm that don't swim well rank high among the main causes of infertility. To give these cells a boost, women trying to conceive can turn to artificial insemination or other assisted reproduction techniques, but success can be elusive. In an attempt to improve these odds, scientists have developed motorized "spermbots" that can deliver poor swimmers—that are otherwise healthy—to an egg. Their report appears in ACS' journal Nano Letters.
Artificial insemination is a relatively inexpensive and simple technique that involves introducing sperm to a woman's uterus with a medical instrument. Overall, the success rate is on average under 30 percent, according to the Human Fertilisation & Embryology Authority of the United Kingdom. In vitro fertilization can be more effective, but it's a complicated and expensive process. It requires removing eggs from a woman's ovaries with a needle, fertilizing them outside the body and then transferring the embryos to her uterus or a surrogate's a few days later.
Each step comes with a risk for failure. Mariana Medina-Sánchez, Lukas Schwarz, Oliver G. Schmidt and colleagues from the Institute for Integrative...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
